In a query of 5 datasets from de novo DLBCL tumors (total of 1295 patient samples), the prevalence of RAS mutations was also very low at diagnosis: 24 of 1295 (1.9%) for KRAS, 10 of 1295 (0.8%) for HRAS, and 1 of 1295 (0.1%) for NRAS2,22–25. Here, KRAS is linked to diffuse large B-cell lymphoma.